Improvements in Frailty Care as Cost Effective

By Staff Writer

January 15, 2024

Frailty care improvements

Frail patients require a robust system during hospital admission to decrease deconditioning risk and hasten discharge. In recent years, a significant effort has gone into quickly identifying these patients. Specialists evaluate them as part of a Frailty Liaison Team. This study examines the effect of these metrics on patient outcomes, as published in the Future Healthcare Journal. 

The Importance of Locating and Transferring Patients at an Early Stage

According to the findings of previous research, proposed internal transfers frequently face delays or may not take place at all. In 2017, hospitals moved three-fifths of fragile patients to appropriate wards. These delays likely influence the duration of hospital stays. This assumption is based on the specialised care frailty units provide. 

A Discussion of the Research Methodology

The Frailty Liaison Team performs the Comprehensive Geriatric Assessment (CGA) on patients classified as frail. These patients receive treatment on the Clinical Decisions Unit (CDU) or the Acute Medical Unit (AMU). This study compares the length of stay for patients transferred to a frailty ward on the assessment day with those transferred after 24 hours. 

The findings of the research study

According to the findings of the study, early transfers result in a hospital stay that is reduced by more than one day. This results in a reduction in direct costs as well as a reduction in the patient’s exposure toward harm that is associated with the hospital. According to this study frailty care improvements could lead to potential annual saving of £26,640.

The Consequences That the Study Could Have

Because of the favourable findings of the study, conversations have begun regarding the possibility of improving the local frailty route. The authors will use the data to identify potential improvements in patient care and compare different discharge procedures. 

The findings of this study emphasise the need of identifying frail individuals at an early stage and transferring them to specialised wards to receive treatment. They have the potential to greatly enhance patient outcomes while also lowering the expense of healthcare. 

 

Reference url

Recent Posts

Fabhalta C3 glomerulopathy treatment
       

Fabhalta C3 glomerulopathy treatment Gains EMA Endorsement as First Targeted Therapy

💡 Have you heard the latest on treatment options for rare kidney diseases?

Novartis’ Fabhalta (iptacopan) has received a positive opinion from the EMA, potentially paving the way for the first approved treatment for C3 glomerulopathy. This first-in-class therapy showed a remarkable 35.1% reduction in proteinuria, promising improved outcomes for patients facing this progressive condition.

Curious about the implications for healthcare and the economy? Dive into the full article to learn how Fabhalta could reshape the landscape for patients with C3G and other complement-mediated diseases.

#SyenzaNews #HealthcareInnovation #DrugDevelopment #MarketAccess

TLX250-CDx imaging agent
      

Zircaix: A Potential Breakthrough in Kidney Cancer Diagnosis

🔍 Could a new imaging agent revolutionize kidney cancer diagnosis?

The FDA’s acceptance of the Biologics License Application for TLX250-CDx marks a significant milestone in the fight against clear cell renal cell carcinoma (ccRCC). This investigational PET imaging tool promises non-invasive, high-accuracy diagnostics, which could lead to improved patient outcomes and better-targeted treatment plans.

Curious about its potential impact on healthcare and market dynamics? Dive into the full article to learn more!

#SyenzaNews #medicalimaging #oncology #HealthcareInnovation

personalized cancer vaccine
         

Personalized Cancer Vaccine in High-Risk Kidney Cancer Patients

🌟 Could personalized cancer vaccines be the future of cancer treatment?

A recent phase I clinical trial has shown promising results for a personalized cancer vaccine in patients with high-risk clear cell renal cell carcinoma (RCC). All participants developed immune responses, and notably, none experienced recurrence at a median follow-up of over 40 months! With a favorable safety profile, this approach may pave the way for more effective adjuvant therapies in oncology.

Jump into the full findings and see how this advancement could change the landscape of cancer treatment!

#SyenzaNews #oncology #biotechnology #innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.